Recruiting Interstitial Cystitis Studies in Memphis
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
The goal of this study is to provide sufficient therapy during the time a patients' B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) risk category is being determined. The ter...
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of t...
A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old
In this study, researchers will learn more about the effects and safety of BIIB141, also known as omaveloxolone or SKYCLARYS®. This drug has been approved, or made available for doctors to prescribe, ...
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
This is a Phase II clinical trial testing the use of two antigen-directed therapies, inotuzumab and blinatumomab, as part of induction therapy for children and young adults with newly diagnosed B-cell...
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go...
Ribociclib (LEE011) Rollover Study for Continued Access
This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-spons...
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
This trial is a limited multi-center, Phase II study to evaluate inotuzumab ozogamicin (Besponsa) in pediatric patients with MRD positive CD22-positive B-lymphoblastic leukemia (B-ALL). Some patients...
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
This is a single-dose, open-label study in pediatric participants with severe SCD and hydroxyurea (HU) failure or intolerance. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9...
About Interstitial Cystitis Clinical Trials in Memphis
Interstitial cystitis/bladder pain syndrome is a chronic condition causing bladder pressure, bladder pain, and sometimes pelvic pain. It primarily affects women and can significantly impact quality of life. Treatment includes dietary changes, bladder instillations, oral medications, and neuromodulation.
There are currently 8 interstitial cystitis clinical trials recruiting participants in Memphis, TN. These studies are seeking a combined 2,000 participants. Research is being sponsored by St. Jude Children's Research Hospital, Novartis Pharmaceuticals, Biogen and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Interstitial Cystitis Clinical Trials in Memphis — FAQ
Are there interstitial cystitis clinical trials in Memphis?
Yes, there are 8 interstitial cystitis clinical trials currently recruiting in Memphis, TN. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Memphis?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Memphis research site will contact you about next steps.
Are clinical trials in Memphis free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Memphis studies also compensate for your time and travel.
What interstitial cystitis treatments are being tested?
The 8 active trials in Memphis are testing new therapies including novel drugs, biologics, and treatment approaches for interstitial cystitis.
Data updated March 2, 2026 from ClinicalTrials.gov